Alphatec (NASDAQ:ATEC) Stock Price Down 6.6% on Insider Selling

Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) traded down 6.6% on Monday after an insider sold shares in the company. The stock traded as low as $10.44 and last traded at $10.62. 327,314 shares were traded during trading, a decline of 81% from the average session volume of 1,717,581 shares. The stock had previously closed at $11.36.

Specifically, COO Scott Lish sold 27,453 shares of the firm’s stock in a transaction on Thursday, February 6th. The stock was sold at an average price of $11.49, for a total value of $315,434.97. Following the sale, the chief operating officer now directly owns 867,677 shares in the company, valued at approximately $9,969,608.73. This trade represents a 3.07 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Patrick Miles sold 43,459 shares of the firm’s stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $11.95, for a total value of $519,335.05. Following the completion of the sale, the chief executive officer now owns 6,065,772 shares in the company, valued at $72,485,975.40. The trade was a 0.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In other Alphatec news, EVP David Sponsel sold 36,256 shares of the firm’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $11.42, for a total value of $414,043.52. Following the sale, the executive vice president now directly owns 735,074 shares in the company, valued at approximately $8,394,545.08. This trade represents a 4.70 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Needham & Company LLC raised their target price on Alphatec from $13.00 to $16.00 and gave the company a “buy” rating in a research note on Monday, January 13th. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Alphatec in a research note on Tuesday, January 14th. Finally, Barclays raised their price target on Alphatec from $20.00 to $21.00 and gave the company an “overweight” rating in a report on Wednesday, January 22nd. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, Alphatec has an average rating of “Moderate Buy” and a consensus target price of $17.56.

Alphatec Trading Down 5.5 %

The business has a fifty day moving average of $10.27 and a 200-day moving average of $8.10. The stock has a market capitalization of $1.52 billion, a price-to-earnings ratio of -8.33 and a beta of 1.43. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.32 and a quick ratio of 1.15.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its holdings in Alphatec by 11.3% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,928,094 shares of the medical technology company’s stock worth $16,280,000 after acquiring an additional 297,850 shares during the period. Barclays PLC grew its holdings in Alphatec by 362.3% during the third quarter. Barclays PLC now owns 170,546 shares of the medical technology company’s stock worth $948,000 after acquiring an additional 133,653 shares during the period. Franklin Resources Inc. grew its holdings in Alphatec by 299.3% during the third quarter. Franklin Resources Inc. now owns 64,450 shares of the medical technology company’s stock worth $343,000 after acquiring an additional 48,308 shares during the period. AlphaCentric Advisors LLC acquired a new position in Alphatec during the third quarter worth about $2,057,000. Finally, Royce & Associates LP grew its holdings in Alphatec by 15.9% during the third quarter. Royce & Associates LP now owns 1,212,286 shares of the medical technology company’s stock worth $6,740,000 after acquiring an additional 165,954 shares during the period. 66.35% of the stock is owned by institutional investors and hedge funds.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.